We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CorePharma Must Divest Two Generic Drugs to Complete Impax Merger
CorePharma Must Divest Two Generic Drugs to Complete Impax Merger
CorePharma will divest generic rights to a dry mouth therapy and a liver drug to clear the way for Impax’s $700 million acquisition of the Middlesex, N.J., drugmaker.